Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison

被引：0
|
作者：
M. Gorschlüter
C. Hahn
A. Fixson
U. Mey
C. Ziske
E. Molitor
R. Horré
T. Sauerbruch
G. Marklein
I. G. H. Schmidt-Wolf
A. Glasmacher
机构：
[1] University of Bonn,Department of Internal Medicine I
[2] University of Bonn,Department of Medical Microbiology and Immunology
来源：
Supportive Care in Cancer | 2003年 / 11卷
关键词：
Neutropenia; Acute leukemia; Febrile infections; Empiric antibiotic therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：362 / 370
页数：8
相关论文
共 50 条
  • [41] Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients (vol 49, pg 26, 2008)
    Hamidah, A.
    Rizall, A. M.
    Nordiah, A. J.
    Jamal, R.
    SINGAPORE MEDICAL JOURNAL, 2008, 49 (02) : 179 - 179
  • [42] Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein
    M. von Lilienfeld-Toal
    M. P. Dietrich
    A. Glasmacher
    L. Lehmann
    P. Breig
    C. Hahn
    I. G. H. Schmidt-Wolf
    G. Marklein
    S. Schroeder
    F. Stuber
    European Journal of Clinical Microbiology and Infectious Diseases , 2004, 23 : 539 - 544
  • [43] Ciprofloxacin plus piperacillin is an equally effective regimen for empiric therapy in febrile neutropenic patients compared with standard therapy
    Griggs, JJ
    Blair, EA
    Norton, JR
    Rowe, JM
    Flesher, WR
    Betts, RF
    AMERICAN JOURNAL OF HEMATOLOGY, 1998, 58 (04) : 293 - 297
  • [44] Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein
    von Lilienfeld-Toal, M
    Dietrich, MP
    Glasmacher, A
    Lehmann, L
    Breig, P
    Hahn, C
    Schmidt-Wolf, IGH
    Marklein, G
    Schroeder, S
    Stuber, F
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (07) : 539 - 544
  • [45] Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial
    Sime, Fekade Bruck
    Roberts, Michael S.
    Tiong, Ing Soo
    Gardner, Julia H.
    Lehman, Sheila
    Peake, Sandra L.
    Hahn, Uwe
    Warner, Morgyn S.
    Roberts, Jason A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (08) : 2369 - 2375
  • [46] A Prospective Randomized Crossover Comparison Between Piperacillin/Tazobactam and Meropenem As Empirical Antibiotic Therapy for Febrile Neutropenia in Children with Hematological and Malignant Disorders
    Sano, Hirozumi
    Kobayashi, Ryoji
    Suzuki, Daisuke
    Hori, Daiki
    Kobayashi, Kunihiko
    BLOOD, 2016, 128 (22)
  • [47] Piperacillin-tazobactam plus netilmicin as empiric treatment for adult patients with acute leukemia, neutropenia, and fever: Single-center experience and retrospective comparison with piperacillin plus netilmicin
    Kern, WV
    Maute, B
    Engel, A
    Heil, G
    Kern, P
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1997, 58 (01): : 56 - 69
  • [48] Comparison Between Piperacillin/Tazobactam and Cefepime Monotherapies as an Empirical Therapy for Febrile Neutropenia in Children With Hematological and Malignant Disorders: A Prospective, Randomized Study
    Sano, Hirozumi
    Kobayashi, Ryoji
    Suzuki, Daisuke
    Kishimoto, Kenji
    Yasuda, Kazue
    Kobayashi, Kunihiko
    PEDIATRIC BLOOD & CANCER, 2015, 62 (02) : 356 - 358
  • [49] Randomized trial of piperacilin/tazobactam versus two regimens of ceftriaxone plus gentamicin in bone marrow transplant patients.
    Rodriguez, G
    Davis, C
    Gingrich, R
    Lee, CK
    Silverman, M
    Hohl, RJ
    BLOOD, 1998, 92 (10) : 337B - 337B
  • [50] Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: A randomized comparison
    Corapcioglu, F
    Sarper, N
    Zengin, E
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2006, 23 (03) : 177 - 186
12345